By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after ...

Patients with obesity have lost up to 15pc of their body weight in trials of a new drug that far outperforms competitors such ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

Eli Lilly & Co.'s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...

Projections show half of ten and 11-year-olds could be overweight or obese in some areas, with experts calling for urgent ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Obesity caused by a high-fat Western diet damages the pancreas, affecting insulin production and blood sugar control even ...

A new report reveals a stark rise in childhood obesity rates across England, with projections showing that more than 40% of ...

In PAH, 5-year mortality is similar with and without obesity, even though patients with obesity have more comorbidities and worse functional capacity.